ADVFN - Advanced Financial Network.
HOME» NYSE » A » ABT Stock Price » ABT Stock News

Abbott Labs Share News

 Abbott Laboratories Stock Price
ABT Stock Price
 Abbott Laboratories Stock Chart
ABT Stock Chart
 Abbott Laboratories Stock News
ABT Stock News
 Abbott Laboratories Company Information
ABT Company Information
 Abbott Laboratories Stock Trades
ABT Stock Trades

Abbott Labs 1Q Net Rose 44% On Strong Drug, Nutritional Sales

DOW JONES NEWSWIRES Abbott Laboratories' (ABT) first-quarter earnings rose 44% as strong drug and nutritional sales contributed to improved margins. The health-care company also raised its full-year earnings guidance by 5 cents, now projecting $5 to $5.10 a share. Abbott's diverse portfolio had cushioned it from some of the problems, like patent expirations and generic competition, facing other large drug makers. But its bottom-line performance has been mixed in recent quarters as restructuring and acquisition charges masked revenue growth. The company has been on a buying spree in recent years in order to reduce its dependence on the anti-inflammatory Humira as the drug's U.S. patent expires in late 2016. Abbott also is in the midst of separating its proprietary drug unit and medical products business into two publicly traded companies by the end of this year. Last month, Abbott named its post-spinoff pharmaceutical company AbbVie, in a nod to the new company's origins and purpose. The health-care company said the name is derived from a combination of Abbott and vie, which references the Latin root vi, meaning life. Abbott Labs reported a profit of $1.24 billion, or 78 cents a share, up from $864 million, or 55 cents, a year earlier. Excluding items such as restructuring, acquisition and integration costs, earnings rose to $1.03 a share from 91 cents. Sales jumped 4.6% to $9.46 billion. Analysts polled by Thomson Reuters had most recently forecast earnings of $1 a share on revenue of $9.37 billion. Operating margin rose to 16.7% from 14.4%. Proprietary pharmaceutical sales, the company's biggest segment by revenue, rose 7.1%. Nutritional sales, which include Similac and Ensure, grew 10%. The established products segment, which focuses on generic sales outside the U.S., saw a 1.6% sales decline. Core laboratory diagnostics sales were up 4.9%. Shares closed Tuesday at $60.43 and were inactive premarket. The stock has gained 9.2% over the past three months. -By Melodie Warner, Dow Jones Newswires; 212-416-2283;

Stock News for Abbott Labs (ABT)
10/24/201617:05:03Current Report Filing (8-k)
10/20/201611:17:00People's Republic of China Clears Abbott Acquisition of Alere
10/20/201603:03:00Business Watch -- WSJ
10/19/201614:52:00Abbott Labs Swings to Loss After Booking Charge on Mylan Stake...
10/19/201612:18:00St. Jude Medical's Sales Rise 12% -- Update
10/19/201610:23:00Abbott Labs Swings to Loss After Booking Charge on Mylan Stake--Update
10/19/201610:10:00St. Jude Medical's Sales Rise 12%
10/19/201609:53:00St. Jude Medical's Sales Rise 12%
10/19/201609:50:00Abbott Labs Swings to Loss After Booking Charge on Mylan Stake
10/19/201609:43:00Abbott Labs Swings to Loss After Booking Charge on Mylan Stake
10/19/201607:53:35Current Report Filing (8-k)
10/19/201607:45:00Abbott Reports Third-Quarter 2016 Results
10/18/201609:20:00Abbott, St. Jude Medical to Sell $1.1 Billion in Assets
10/18/201608:00:00St. Jude Medical and Abbott to Sell Portion of Vascular Closure...
10/18/201608:00:00St. Jude Medical and Abbott to Sell Portion of Vascular Closure...
10/17/201622:10:00St. Jude Medical Forms Cybersecurity Advisory Group
10/17/201621:20:00St. Jude Medical Forms Cybersecurity Advisory Group
10/14/201611:15:00The Innovation of Wearable Technology and Medical Devices
10/13/201620:40:00INVESTOR ALERT: Khang & Khang LLP Announces an Investigation...
10/13/201618:40:00SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On...

Abbott Laboratories and other New York Stock Exchange stock quotes are delayed by at least 20 minutes.
All other stock price data is delayed by at least 15 minutes unless otherwise stated.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2016 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations